S. Baize, D. Pannetier, L. Oestereich, T. Rieger and L. Koivogui, Emergence of Zaire Ebola virus disease in Guinea-preliminary report, N Engl J Med, vol.371, pp.1418-1425, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01011799

DOI : 10.1056/NEJMoa1404505

J. Kuhn, K. Andersen, S. Baize, Y. Bào and S. Bavari, Nomenclature-and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014, Viruses, vol.6, p.25421896, 2014.
DOI : 10.3390/v6114760

, World Health Organization. Ebola virus disease (EVD) in West Africa: an extraordinary epidemic, Wkly Epidemiol Rec, vol.90, pp.89-96, 2015.

E. Leroy, S. Baize, V. Volchkov, S. Fisher-hoch, M. Georges-courbot et al., Human asymptomatic Ebola infection and strong inflammatory response, Lancet, vol.355, p.10881895, 2000.

H. Feldmann and T. W. Geisbert, Ebola haemorrhagic fever, Lancet, vol.377, issue.10, p.21084112, 2011.

T. E. West and A. Von-saint-andré-von-arnim, Clinical presentation and management of severe Ebola virus disease, Ann Am Thorac Soc, vol.11, 2014.

J. S. Schieffelin, J. G. Shaffer, A. Goba, M. Gbakie, S. K. Gire et al., Clinical illness and outcomes in patients with Ebola in Sierra Leone, N Engl J Med, vol.371, pp.2092-2100, 2014.

D. S. Stephens, B. S. Ribner, B. D. Gartland, N. R. Feistritzer, M. M. Farley et al., Ebola virus disease: experience and decision making for the first patients outside of Africa, PLoS Med, vol.12, p.1001857, 2015.

G. M. Lyon, A. K. Mehta, J. B. Varkey, K. Brantly and L. Plyler, Clinical care of two patients with Ebola virus disease in the United States, N Engl J Med, vol.371, pp.2402-2409, 2014.
DOI : 10.1056/NEJMoa1409838

M. Mora-rillo, M. Arsuaga, G. Ramirez-olivencia, F. De-la-calle, A. M. Borobia et al., Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease, Lancet Respir Med, vol.3, pp.554-562, 2015.
DOI : 10.1016/s2213-2600(15)00180-0

, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola, 2015.

S. J. Smither, L. S. Eastaugh, J. A. Steward, M. Nelson, R. P. Lenk et al., Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, pp.153-155, 2014.

Y. Furuta, B. B. Gowen, K. Takahashi, K. Shiraki, D. F. Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, p.24084488, 2013.

Y. Furuta, K. Takahashi, Y. Fukuda, M. Kuno, T. Kamiyama et al., In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother, vol.46, pp.977-981, 2002.

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, p.24583123, 2014.

M. , Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in Adults, ClinicalTrials.gov, 2013.

V. Madelain, L. Oestereich, F. Graw, T. Nguyen, X. De-lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral Res, vol.123, pp.70-77, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-01196078

F. Mentre, A. M. Taburet, J. Guedj, X. Anglaret, S. Keita et al., Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, pp.150-151, 2014.

N. Bouazza, J. Treluyer, F. Foissac, F. Mentré, A. Taburet et al., Favipiravir for children with Ebola, Lancet, vol.385, pp.603-604, 2015.

A. K. Rowe, J. Bertolli, A. S. Khan, R. Mukunu, J. J. Muyembe-tamfum et al., Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, J Infect Dis, vol.179, p.9988162, 1999.

T. Ksiazek, P. Rollin, A. Williams, D. Bressler, M. Martin et al., Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, J Infect Dis, vol.179, p.9988182, 1995.

J. S. Towner, P. E. Rollin, D. G. Bausch, A. Sanchez, S. M. Crary et al., Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome, J Virol, vol.78, p.15047846, 2004.

A. P. Kourtis, K. Appelgren, M. S. Chevalier, and A. Mcelroy, Ebola virus disease: focus on children, Pediatr Infect Dis J, vol.34, p.25831417, 2015.

P. E. Rollin, D. G. Bausch, and A. Sanchez, Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus, J Infect, vol.196, pp.364-71, 2007.

M. G. Kortepeter, D. G. Bausch, and M. Bray, Basic clinical and laboratory features of filoviral hemorrhagic fever, J Infect Dis, vol.204, p.21987756, 2011.

E. I. Bah, M. Lamah, T. Fletcher, S. T. Jacob, D. M. Brett-major et al., Clinical presentation of patients with Ebola virus disease in Conakry, Guinea, N Engl J Med, vol.372, pp.40-47, 2015.

, Ebola in West Africa-Guinea: resistance to the Ebola response. ACAPS Thematic Note, ACAPS, 2015.

P. Calain and M. Poncin, Reaching out to Ebola victims: coercion, persuasion or an appeal for self-sacrifice?, Soc Sci Med, vol.147, pp.126-133, 2015.

, Presidential Commission for the Study of Bioethical Issues. Ethics and Ebola: public health planning and response, 2015.

Y. Huang, H. Wei, Y. Wang, Z. Shi, H. Raoul et al., Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays, Virol Sin, vol.27, pp.273-277, 2012.

N. T. Tam, N. T. Huy, L. Thoa, N. P. Long, N. Trang et al., Participants understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis, Bull World Health Organ, vol.93, pp.186-198, 2015.

J. Whitehead, The design and analysis of sequential clinical trials, 1997.

R. Newcombe, Two-sided confidence intervals for the single proportion: comparison of seven methods, Stat Med, vol.17, p.9595616, 1998.

B. Hidalgo and M. Goodman, Multivariate or multivariable regression, Am J Public Health, vol.103, p.23153131, 2013.
DOI : 10.2105/ajph.2012.300897

URL : http://europepmc.org/articles/pmc3518362?pdf=render

J. Copas, Plotting p against x, Appl Stat, vol.32, pp.25-31, 1983.
DOI : 10.2307/2348040

S. Sissoko, E. Folkesson, M. Abdoul, A. Beavogui, S. Gunther et al., Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Abstract 103-ALB. 22nd Conference on Retroviruses and Opportunistic Infections, pp.23-26, 2015.

W. Seattle and U. S. Available,

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Comput Stat Data Anal, vol.49, pp.1020-1038, 2005.

K. R. Victory, F. Coronado, S. O. Ifono, T. Soropogui, and B. A. Dahl, Centers for Disease Control and Prevention. Ebola transmission linked to a single traditional funeral ceremony-Kissidougou, Guinea, MMWR Morb Mortal Wkly Rep, vol.64, p.25879897, 2014.

S. Lanini, A. Zumla, J. Ioannidis, A. D. Caro, S. Krishna et al., Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?, Lancet Infect Dis, vol.15, pp.738-745, 2015.

S. Joffe, Evaluating novel therapies during the Ebola epidemic, JAMA, vol.312, pp.1299-1300, 2014.

. Chimerix, An open-label, multicenter study of the safety and anti viral activity of brincidofovir (BCV, CMX001) for Ebola virus disease, ClinicalTrials.gov, 2014.

J. Griensven, T. Edwards, X. De-lamballerie, M. G. Semple, P. Gallian et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med, vol.374, issue.1, pp.33-42, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01252702

, Putative investigational therapeutics in the treatment of patients with known Ebola infection, ClinicalTrials.gov, 2015.

X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.514, pp.47-53, 2014.

B. S. Cooper, M. F. Boni, W. Pan-ngum, N. P. Day, P. W. Horby et al., Evaluating clinical trial designs for investigational treatments of Ebola virus disease, PLoS Med, vol.12, p.25874579, 2015.

C. Adebamowo, O. Bah-sow, F. Binka, R. Bruzzone, A. Caplan et al., Randomised controlled trials for Ebola: practical and ethical issues, Lancet, vol.384, issue.14, p.25390318, 2014.

A. Sanchez, M. Lukwiya, D. Bausch, S. Mahanty, A. J. Sanchez et al., Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels, J Virol, vol.78, p.15367603, 2004.

A. K. Mcelroy, B. R. Erickson, T. D. Flietstra, P. E. Rollin, S. T. Nichol et al., Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome, J Infect Dis, vol.210, pp.558-566, 2014.

G. Fitzpatrick, F. Vogt, M. Gbabai, O. B. Decroo, T. Keane et al., The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola case management centre, J Infect Dis, vol.212, pp.1752-1758, 2014.

L. Hunt, A. Gupta-wright, V. Simms, F. Tamba, V. Knott et al., Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study, Lancet Infect Dis, vol.15, issue.15, p.26271406, 2015.

M. Schibler, P. Vetter, P. Cherpillod, T. J. Petty, C. S. Vieille et al., Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report, Lancet Infect Dis, vol.15, pp.1034-1040, 2015.

D. C. Angus and T. Van-der-poll, Severe sepsis and septic shock, N Engl J Med, vol.369, pp.840-851, 2013.

R. Bellomo, J. A. Kellum, and C. Ronco, Acute kidney injury, Lancet, vol.380, issue.11, p.22617274, 2012.

N. F. Crum-cianflone, Bacterial, fungal, parasitic, and viral myositis, Clin Microbiol Rev, vol.21, pp.473-494, 2008.
DOI : 10.1128/cmr.00001-08

URL : https://cmr.asm.org/content/21/3/473.full.pdf

R. J. Konrad, D. B. Goodman, and W. L. Davis, Tumor necrosis factor and coxsackie B4 rhabdomyolysis, Ann Intern Med, vol.119, p.861, 1993.
DOI : 10.7326/0003-4819-119-8-199310150-00024

C. Naylor, A. Jevnikar, and N. Witt, Sporadic viral myositis in two adults, CMAJ, vol.137, p.2832046, 1987.

X. Bosch, E. Poch, and J. M. Grau, Rhabdomyolysis and acute kidney injury, N Engl J Med, vol.361, pp.62-72, 2009.

, Experimental Treatment with Favipiravir for Ebola Virus Disease, PLOS Medicine, 2016.

P. Ramanan, R. S. Shabman, C. S. Brown, G. K. Amarasinghe, C. F. Basler et al., Filoviral immune evasion mechanisms, Viruses, vol.3, pp.1634-1649, 2011.
DOI : 10.3390/v3091634

URL : https://www.mdpi.com/1999-4915/3/9/1634/pdf

P. Ramanan, M. R. Edwards, R. S. Shabman, D. W. Leung, A. C. Endlich-frazier et al., Structural basis for Marburg virus VP35-mediated immune evasion mechanisms, Proc Natl Acad Sci U S A, vol.109, pp.20661-20666, 2012.

M. Broadhurst, J. Kelly, A. Miller, A. Semper, D. Bailey et al., ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study, Lancet, vol.386, pp.867-874, 2015.

B. B. Gowen, E. J. Sefing, J. B. Westover, D. F. Smee, J. Hagloch et al., Alterations in favipiravir (T705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, pp.132-137, 2015.

J. M. Varghese, J. A. Roberts, and J. Lipman, Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock, Crit Care Clin, vol.27, pp.19-34, 2011.